News

1NVAX : Uncovering Potential: Novavax's Earnings Preview
Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19. The market awaits Novavax's ...
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and ...
Novavax to Participate in BofA Securities 2025 Health Care Conference
Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference.
Novavax Announces Improved Financial Terms In Its Agreement With Takeda For Nuvaxovid In Japan
Novavax, Inc. (NVAX) said it has updated the terms of the collaboration and licensing agreement with Takeda. The company noted that the improved financial terms of the amended ...
Vinay Prasad to head FDA division regulating vaccines
The U.S. FDA has appointed Vinay Prasad to be the next director of its Center for Biologics Evaluation and Research division ...
Novavax (NasdaqGS:NVAX) And Takeda Amend Collaboration For SARS-CoV-2 Vaccine In Japan
Novavax (NasdaqGS:NVAX) recently amended its collaboration agreement with Takeda, enhancing its revenue potential through a new upfront payment structure and future royalties. These developments, ...